We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.49%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.36B
AUM Growth
-$287M
Cap. Flow
-$74.9M
Cap. Flow %
-0.8%
Top 10 Hldgs %
76.51%
Holding
102
New
8
Increased
20
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$42.6M
2
BCYC
Bicycle Therapeutics
BCYC
+$31.8M
3
GRAL
GRAIL Inc
GRAL
+$26.5M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$22M
5
RVMD icon
Revolution Medicines
RVMD
+$18.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$212M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$17.4M
3
TNGX icon
Tango Therapeutics
TNGX
+$5.78M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.31M
5
BMEA icon
Biomea Fusion
BMEA
+$5.24M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
51
Structure Therapeutics
GPCR
$3.39B
$9.81M 0.1%
361,565
+276,065
+323% +$9.79M
VERV
52
DELISTED
Verve Therapeutics
VERV
$9.54M 0.1%
1,691,530
– –
OPT
53
DELISTED
Opthea Limited American Depositary Shares
OPT
$8.54M 0.09%
2,173,622
– –
TCRX icon
54
TScan Therapeutics
TCRX
$48.1M
$8.47M 0.09%
2,784,792
– –
KALA icon
55
KALA BIO
KALA
$11.7M
$8.34M 0.09%
24,038
+6,211
+35% +$1.96M
VIR icon
56
Vir Biotechnology
VIR
$1.45B
$7.96M 0.09%
+1,084,539
New +$8.55M
MIRM icon
57
Mirum Pharmaceuticals
MIRM
$6.58B
$7.88M 0.08%
190,476
– –
ARVN icon
58
Arvinas
ARVN
$525M
$7.77M 0.08%
405,576
– –
NTLA icon
59
Intellia Therapeutics
NTLA
$1.5B
$7.51M 0.08%
+644,116
New +$10.1M
TSVT
60
DELISTED
2seventy bio
TSVT
$7.34M 0.08%
2,497,526
– –
TSHA icon
61
Taysha Gene Therapies
TSHA
$1.58B
$6.93M 0.07%
4,004,756
– –
CLDX icon
62
Celldex Therapeutics
CLDX
$2.84B
$6.26M 0.07%
247,644
– –
BMEA icon
63
Biomea Fusion
BMEA
$88.9M
$5.63M 0.06%
1,451,990
-656,959
-31% -$5.24M
FATE icon
64
Fate Therapeutics
FATE
$266M
$5.38M 0.06%
3,258,402
+260,630
+9% +$657K
BNTX icon
65
BioNTech
BNTX
$23.4B
$5.13M 0.05%
+45,031
New +$5.14M
IRON icon
66
Disc Medicine
IRON
$2.8B
$4.88M 0.05%
+77,050
New +$4.46M
RLAY icon
67
Relay Therapeutics
RLAY
$3.95B
$4.78M 0.05%
1,160,117
– –
CTNM
68
Contineum Therapeutics
CTNM
$533M
$4.58M 0.05%
312,500
– –
DBVT
69
DBV Technologies
DBVT
$799M
$4.52M 0.05%
1,461,425
-1
-0% -$3
SGMT icon
70
Sagimet Biosciences
SGMT
$435M
$4.29M 0.05%
952,996
-428,902
-31% -$2.17M
WVE icon
71
Wave Life Sciences
WVE
$1.1B
$4.26M 0.05%
344,063
– –
SKYE icon
72
Skye Bioscience
SKYE
$21.2M
$4.11M 0.04%
1,450,638
+16,004
+1% +$66.9K
PCVX icon
73
Vaxcyte
PCVX
$7.62B
$4M 0.04%
48,885
– –
SANA icon
74
Sana Biotechnology
SANA
$852M
$3.88M 0.04%
2,380,949
– –
CYPH
75
Cypherpunk Technologies Inc
CYPH
$63.1M
$3.37M 0.04%
1,172,175
– –
1 2
3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Baker Bros. Advisors held 102 positions worth $9.36B, down 3% from $9.65B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors's Q4 2024 filing shows 8 new, 20 increased, 5 reduced and 7 closed positions. Its largest new stake was GRAIL Inc: 1,630,125 shares worth $29.1M. The largest sale was BeOne Medicines Ltd, an estimated $212M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2024 buy was GRAIL Inc: 1,630,125 shares worth $29.1M.
  • Baker Bros. Advisors added most to Insmed in Q4 2024, an estimated $42.6M increase.
  • Baker Bros. Advisors's biggest Q4 2024 reduction was BeOne Medicines Ltd, cutting an estimated $212M.
  • Baker Bros. Advisors fully exited Tango Therapeutics in Q4 2024, selling an estimated $5.78M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $9.36B portfolio in Q4 2024.
  • Baker Bros. Advisors opened 8 new positions and closed 7 in Q4 2024.
  • Baker Bros. Advisors's portfolio value fell 3% quarter-over-quarter to $9.36B.

Based on Baker Bros. Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.